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本文 
 胃や肝臓等前方の消化器官は、前腸と呼ばれる管から生じる。前腸の腹側正
中は甲状腺や肺、肝臓の原基が形成される特別な領域であり、原基が形成され
る以前から腹側に突き出た特徴的な形状をしている。先行研究では各消化器官
の領域化、分化に必要なシグナル伝達経路が複数同定されている。しかし、腹
側正中領域の形成に関与する分子や、適切な領域でシグナルを伝達し、各消化
器官の領域を決めるメカニズムは不明である。 
当研究室では前腸の腹側にGlypican-3が特異的に発現していることを明らか
にした。Glypican-3 は膜結合型プロテオグリカンの１つであり、糖鎖を介して
他シグナルリガンドを集積することで、シグナル勾配の形成や局所的なシグナ
ルの受容を可能とする。ショウジョウバエ胚では、プロテオグリカンが Wnt フ
ァミリー増殖因子リガンドの受容体への結合を促進していることが報告された
(Tsuda et al., 1999)。また Glypican-3 ノックアウトマウスでは組織が巨大化し
た表現型を示すことが報告されており(Gonzalez et al., 1998)、Glypican-3 は細
胞移動や分裂にも関与していると示唆されている。しかしニワトリ胚における
Glypican-3 の機能は未だ不明である。私は Glypican-3 が腹側正中領域の形成や
シグナル伝達に関与し、消化器官の領域決定に寄与しているのではないかと考
え、Gypican-3 の機能解析を行うことにした。 
 前腸が形成される過程での細胞挙動の詳細な記載がなかったため、まず前腸
内胚葉細胞をラベルした胚を培養し、前腸形成に伴う細胞配置の変化を観察し
た。Stage 7~9 の前腸門の細胞は、Stage 10~11 では前後軸に沿って前腸腹側の
広範囲に寄与するが、Stage 11 以降の前腸門の細胞は広範囲に広がらなくなる
ことが明らかになった。また Stage 7~8 の前腸門の正中付近の細胞は、前腸の
伸長と共に正中線上に配置されることが分かった。次に前腸が伸長する時期に
BrdU を取り込ませ、分裂した細胞を検出した。前腸門付近の内胚葉で BrdU 陽
 性細胞が多数観察された。前腸腹側側方内胚葉では BrdU 陽性細胞が観察され
たが、腹側正中の内胚葉では BrdU 陽性細胞がほとんど検出されなかった。以
上の結果から、Stage 7~10 における前腸の伸長は主に前腸門からの細胞の供給
によって起こり、腹側正中では分裂が起こらず、細胞移動によって細胞が供給
されることが分かった。 
 ニワトリでは Glypican-3 の遺伝子配列が決定されていなかったため、CDS
全長のクローニングを行った。また 3’RACE 法、5’RACE 法を用いて UTR の塩
基配列を解析した。クローニングで得られた塩基配列を基に RNA プローブを合
成して Whole mount in situ hybridization を行い、Glypican-3 の発現パターン
を詳細に解析した。Stage 8 では前腸の腹側全体で強いシグナルが観察されたが、
Stage 9 以降は正中付近で発現が強くなることが明らかとなった。Glypican-3
の機能を解析するため、強制発現コンストラクトと siRNA を設計した。現在
siRNA のターゲット特異性とノックダウン効率を検証している。 
 今後は、Glypican-3 強制発現胚・ノックダウン胚の細胞挙動を観察し、
Glypican-3 が正常な前腸形成・正中領域の形成に関与しているのか検証する予
定である。また各消化器官のマーカー遺伝子発現や、シグナル伝達強度の変化
を観察し、Glypican-3 が前腸でシグナル伝達制御に関与しているのか明らかに
したい。 
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Summary 
 
Anterior part of primitive digestive tract, the foregut provides various organs and also 
affects patterning of the anterior neural tissue and development of the heart. It is important to 
understand the mechanisms of the foregut formation which controls whole anterior 
embryogenesis. Foregut formation is initiated from HH Stage 6 by folding at the anterior tip of 
the embryo. The foregut is like a shallow sac in the beginning and subsequently, foregut 
elongates rapidly toward caudal. A few reports suggested that the midline cells in the anterior 
intestinal portal (AIP) are important for the foregut elongation in stage 7. 
In the present thesis, to understand the mechanisms of the foregut elongation, the fate 
of the midline cells in AIP was analyzed at the various stages. I found that the midline cells in 
AIP expanded widely into the ventral midline of the foregut until stage 9 and this expansion of 
AIP cells gradually restricted to posterior as the foregut formation progressed. In addition, 
proliferating cells in the ventral foregut during the foregut elongation were detected by BrdU 
treatment. Proliferating cells were found in whole ventral foregut between stage 6, before the 
foregut formation, and 8, but no proliferating area was found in the ventral midline between 
stage 7 and 9, during rapid foregut elongation. These results indicate that endodermal cells in 
the ventral midline of the foregut didn’t proliferate during the foregut elongation but 
presumptive ventral midline endoderm proliferates before foregut formation. The ventral 
midline cells were provided from AIP, so it is suggested that endodermal cells which contribute 
to the ventral midline proliferate and be stocked in AIP before the foregut elongation in order 
to supply sufficient number of cells for the ventral midline during the foregut elongation. Then 
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non-proliferating area in the ventral midline was restricted posteriorly as the foregut developed. 
This area was consistent with the expansion area from AIP in almost the same developmental 
stage. Those observations suggested that the ventral midline of the foregut extends by only cell 
rearrangement from AIP. 
Next, Glypican-3 was cloned and its expression pattern was analyzed. Glypican-3 
expressed in the ventral foregut, may control cell proliferation, rearrangement and specification 
in the ventral midline of the foregut via regulation of signaling such as Wnt, BMP, FGF and 
Shh. In this thesis full-length protein coding sequence of Glypican-3 was isolated. From 
expression pattern analysis, Glypican-3 was expressed in the presumptive foregut endoderm at 
stage 5 and 6, and strongly in the ventral midline endoderm of the foregut from stage 7 to 10. It 
is possible that Glypican-3 is involved in the cell rearrangement of the ventral midline from 
AIP in these stages. After stage 11 expression of Glypican-3 was restricted in thyroid, lung and 
liver primordia. Later stages, Glypican-3 may control differentiation of specific organs. 
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Introduction 
 
The digestive tract is composed of a variety of digestive organs, such as esophagus, 
stomach and intestine. Developing digestive organs are divided into three parts along with an 
anterior-posterior axis: foregut, midgut and hindgut. Epithelium is present in all parts of the gut, 
and it is originated from endoderm and surrounding mesodermal mesenchyme. Before gut tube 
formation, endoderm, situated in the ventral side of the embryo, shows flat sheet-like structure 
until HH stage 5 (Hamburger and Hamilton, 1951). Foregut formation is initiated from stage 6 
through the folding of the anterior tip of the embryo. In the beginning, foregut is like a shallow 
sac and subsequently, it elongates rapidly caudally to make a tube structure. This elongation is 
much faster than body elongation, so the posterior end of the foregut, the anterior intestinal 
portal (AIP), moves posteriorly. Then, the posterior end of embryo also folds to make another 
sac-like structure, the hindgut. The opening between foregut and hindgut is the midgut. The 
hindgut elongates anteriorly, eventually resulting in the disappearance of the midgut and the 
completion of the whole gut tube formation. 
In the reports by Bellairs 1953a, 1953b, 1955, 1957, presumptive foregut area, cell 
movement and cell proliferation were analyzed. However, mechanisms to support such rapid 
elongation of the foregut are still unclear. Foregut elongation is required for normal patterning 
of anterior neural tissue and development of heart in the chicken embryo (Withington et al., 
2001). One of the key parts for the foregut elongation is the midline cells in AIP. When the 
midline endodermal cells in AIP were labelled at stage 7, labeled cells were found in the 
ventral midline of the entire foregut at stage 10 (Kirby et al., 2003). Ablation of midline of AIP 
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resulted in the defect of the foregut elongation (Withington et al., 2001). Those reports 
suggested that extension of the ventral midline in the foregut by providing the midline 
endodermal cells in AIP drives the foregut elongation. To understand the mechanism of the 
foregut elongation, I focused on two questions: when the ventral extension in the foregut 
occurs and whether this extension is provided by cell rearrangement and/or cell proliferation. 
Following the foregut formation, the organ specification occurs in foregut endoderm. 
In the foregut, digestive organs, such as pharynx, esophagus, stomach, liver, and pancreas, 
respiratory organs, such as lung and trachea, endocrine organs, such as thyroid and parathyroid, 
and lymph organs develop. Especially from the ventral midline of the foregut, primordia of 
liver, lung and thyroid plunge into the adjacent mesenchyme to form buds. Before formation of 
those organ primordia, each endoderm already was regionalized and expressed specific marker 
genes localized along the ventral midline of the foregut. The expression of these genes is 
controlled by several signaling pathways. For example, Wnt signaling plays a role in 
specifying lung endoderm progenitors. Nkx2.1, the earliest marker of the lung endoderm, is 
expressed in the presumptive lung endoderm at the ventral midline of the foregut. In mice, 
lacking of Wnt2/2b expression exhibits loss of Nkx2.1 expression and complete lung agenesis 
(Goss et al., 2009). Liver specification and differentiation require BMP signaling. 
Overexpression of BMP4 exhibits expansion of Hex, the earliest marker of the liver, and this 
ectopic expression of Hex was only found in the ventral midline (Okayama, 
unpublished).Taken together, the ventral midline in the foregut transmits many signaling in the 
same period to control regionalization of various organ progenitors. However, there are little 
reports to find out how the organ specification is regulated correctly on the ventral midline of 
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the foregut. 
It has been reported that Glypican-3 is expressed strongly in the ventral foregut 
endoderm (Kimura et al., 2011). Glypican-3 is one of heparan sulfate proteoglycans that are 
bound to the exocytoplasmic surface of plasma membrane by a glycosyl-phosphatidylinositol 
anchor (Lander et al., 1996). Proteoglycans collect various signaling ligands through their 
sugar chains. Studies in Drosophila have shown that Dally, one of Glypican family, can 
influence Wingless and Decapentaplegic signaling (Tsuda et al., 1999). In mice, Glypican-3 
inhibits Hedgehog signaling during development by competing with patched for Hedgehog 
binding (Capurro et al., 2008). Loss-of-function mutations in the human Glypican-3 gene result 
in the Simpson-Golabi-Behmel syndrome, characterized by severe malformations and 
overgrowth (Davoodi et al., 2007). Overexpression of Glypican-3 promotes proliferation, 
regulates cell cycle progression, and inhibits apoptosis of human fetal osteoblastic cell line 
(Cai et al., 2017). From the above, it is suggested that Glypican-3 is involved in regulation of 
various signal transduction, cell viability and proliferation. The detailed expression and 
functions of Glypican-3 in the chick embryo are still unknown, and therefore, I focused on 
Glypican-3 as the candidate that is involved in the foregut formation and organ regionalization. 
I isolated full-length protein coding sequence (CDS) of Glypican-3, analyzed its expression 
pattern during the foregut formation and discussed about the functions of Glypican-3 in the 
foregut. 
 
 
 
 8 
 
Materials and Methods 
 
Chicken embryos 
Fertilized eggs were incubated at 38°C for the appropriate time to obtain embryos of 
the required stage. The embryo was defined based on Hamburger and Hamilton, 1951.  
 
New culture 
Embryos were cultured with the modified New method (Stern and Ireland 1981). 
 
Cell labeling with DiI 
0.05% Carbocyanine dye DiI, (1,1-dioctadecyl-3,3,3’,3’-tetramethyl 
indocarbocyanine perchlorate) (DiI-C18; Molecular Probes) in 30mM sucrose solution was 
used to label cells with microcapillary pipettes. 
 
5-Bromodeoxyuridine (BrdU) labeling 
10mM BrdU in DMSO was diluted to 10µM with physiological saline. 300µl of 
BrdU solution heated at 38℃ was dropped onto the embryos in the New culture and incubated 
at 38℃ for 8 hours. After incubation, the embryos were washed 5 times with physiological 
saline and fixed with 4% paraformaldehyde in PBS. The embryos were dehydrated using a 
series of baths of increasing concentrations of ethanol and xylene, embedded in paraffin and 
sectioned at 7µm.  
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BrdU-immunohistochemistry 
Sections were deparaffinized with xylene and hydrated in decreasing concentrations 
of ethanol and finally replaced in PBS. To enhance the binding of the anti-BrdU monoclonal 
antibody, the sections were processed with 100µg/ml of Proteinase-K for 10 minutes at 37℃ 
and 1N HCl for 45 minutes at room temperature. The sections were blocked by 10% goat 
serum in PBS/0.1% tween 20 for 1 hour at room temperature. After blocking, sections were 
incubated with the rat anti-BrdU monoclonal antibody, at final concentration 1:400 in blocking 
solution overnight at 4℃. Then, the sections were washed four times for 10 minutes with 
PBS/0.1% tween 20 and treated with the anti-rat IgG Rhodamine, final concentration 1:500 in 
blocking solution for 1 hour at 37℃. Finally, the sections were washed three times for 10 
minutes with PBS/0.1% tween 20 and counter-stained with DAPI (nacalai tesque) diluted to 
1:2000 in TBST for 15 minutes at room temperature. 
 
mRNA extraction 
50 whole embryos at day-2 or day-3 were replaced into dish on ice and 
extraembryonic organization was removed. Embryos were washed with physiological saline. 
After washing, embryos were placed into empty tube. mRNA was extracted using TRIZOL 
Reagent (Invitrogen) according to the manufacturer’s protocol. 
 
cDNA synthesis 
 Using total RNAs from 2 or 3-day-old chicken embryo described above as templates, 
cDNA were synthesized with PrimeScript Reverse Transcriptase (TaKaRa) according to the 
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manufacturer’s protocol. 
 
RT-PCR 
PCR was performed with ExTaq DNA polymerase (TaKaRa) using the following 
parameters : initial denature at 98℃ for 5 minutes, and 30 cycles of (denaturation at 98℃ for 
10 seconds, annealing at 60.5℃ for 30 seconds, elongation at 72℃ for 2 minutes) or 
PrimeStar HS DNA polymerase (TaKaRa) using the following parameters : initial denature at 
98℃ for 5 minutes, and 30 cycles of (denaturation at 98℃ for 10 seconds, annealing at 
60.5℃ for 5 seconds, elongation at 72℃ for 2 minutes). Gene specific primers for RT-PCR 
were designed according to the predicted sequence of Glypican-3 (XM_001232891.3) in the 
National Center for Biotechnology Information (NCBI). The following primers were used for 
PCR to obtain the product for cloning to pGEM-T Easy Vector (Promega). 
  forward, 5’-CGGGAGGATGTCGGGGAG-3’ 
reverse, 5’-TCCTTTGCCCTGTCTTTGGCAATG-3’ 
The following primers were used for nested PCR. 
forward, 5’-ATGTCGGGGAGCGGCGGA-3’ 
reverse, 5’-GAGAGCTTTCCTCCATTCTTCTGCA-3’ 
The following primers were used for PCR to obtain the product for cloning to 
pME18S-FL3 Vector. 
forward, 5’-AATGAATTCGGGAGGATGTCGGGGAG-3’ 
reverse, 5’-ATAGCGGCCGCTCCTTTGCCCTGTCTTTG-3’ 
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DNA sequencing 
Plasmid DNA was purified with Gel Extraction Kit (QIAGEN) from each clone and 
sequenced using Premix2 DNA sequencing service (FASMAC Corporation). The following 
primers for sequencing were designed according to the predicted sequence of Glypican-3 
(XM_001232891.3) in NCBI: 5’-CGGGAGGATGTCGGGGAG-3,  
5’-GCCACTGCCTGGTACTTCTC-3, 5’-TCATCCAGAATGCTGCTGTC-3, 
5’-GAGGGGTTGACCAAGGGTAT-3, 5’-GAGAGCTTTCCTCCATTCTTCTG-3, 
5’-AGGAATGGAGCAAAAGCTCA-3 and 5’-TCCTTTGCCCTGTCTTTGGCAATG-3. 
 
PCR 
Plasmid DNA of Glypican-3 and ΔGlypican-3 in pME18S-FL3 was purified with Gel 
Extraction Kit (QIAGEN) and used as a template. PCR was performed with ExTaq DNA 
polymerase (TaKaRa) using the following parameters : initial denature at 98℃ for 5 minutes, 
and 30 cycles of (denaturation at 98℃ for 10 seconds, annealing at 57℃ for 30 seconds, 
elongation at 72℃ for 35 seconds) Exon 6 specific forward primer and Exon 8 specific 
reverse primer for PCR were designed according to the predicted sequence of Glypican-3 
(XM_001232891.3) in NCBI. 
  forward, 5’-AGGAATGGAGCAAAAGCTCA-3’ 
reverse, 5’-TCCTTTGCCCTGTCTTTGGCAATG-3’ 
 
Whole-mount in situ hybridization (WISH) 
PCR products were purified with Gel Extraction Kit (QIAGEN) and cloned into 
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pGEM-T easy vector (Promega) according to the manufacturer’s instruction. WISH probe of 
Glypican-3 was synthesized with DIG-RNA labeling mix (Roche) following manufacturer’s 
instruction. The embryos were fixed with 4% paraformaldehyde in PBS and replaced in 100% 
methanol overnight at 4℃. WISH was carried out as previously described (Stern, 1998). 
Stained embryos were embedded with paraffin and sectioned at 10µm. 
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Results 
 
The ventral midline of the foregut extends before stage 10 with cells provided from AIP. 
The midline of AIP in stage 7 gives rise to whole ventral midline of the foregut in 
stage 10 (Kirby et al., 2003). This means cells provided from the midline of AIP were involved 
in the ventral midline extension. To determine until when this cell supply from the midline of 
AIP was maintained, the midline endodermal cells of AIP were labeled with DiI and traced 
during the foregut formation. Cells labelled at stage 7
+
 spread widely into the ventral midline 
along with anterior-posterior axis at stage 11 (Figures 1A and B). Cells labelled at stage 9 
elongated into the middle and posterior part of the ventral midline of the foregut at stage 12 
(Figures 1C and D). No labelled cells were found in anterior part of the ventral midline. Cells 
labelled at stage 10 showed only slight expansion at the posterior part of the ventral midline at 
stage 11(Figures 1E and F). Cells labelled at stage 11, 12 and 13 showed no movement or 
expansion and kept their position at AIP in stage 14, 15 and 14 respectively (Figures 1G-L). 
Taken together, midline cells of AIP up to stage 9 spread widely into the ventral midline, 
whereas midline cells of AIP after stage 10 stopped to expand and stay at AIP. Therefore before 
stage 10, the ventral midline extends by cells provided from AIP.  
 
 
The ventral midline endodermal cells do not proliferate during the ventral midline 
extension. 
In the previous experiments midline cells in AIP expanded into entire ventral midline 
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of the foregut. To know whether the cell proliferation and/or cell rearrangements drive this 
expansion, proliferating cells were detected using 5-Bromodeoxyuridine (BrdU), which has 
been used as a specific marker of the cells that synthesized DNA (Gratzner, 1982, Lacy et al., 
1991). Embryos in various stages were incubated with BrdU for 8 hours and proliferating cells 
in 8 hours were determined using immunostaining. Between stage 6 and 8, proliferating cells 
were observed in the whole foregut endoderm (Figures 2B, C and D). Proliferating cells were 
detected in the lateral (Figures 2B’’, C’’ and D’’) and the ventral midline (Figures 2B’, C’ and 
D’) endoderm of the entire foregut. Between stage 7 and 9, there were many proliferating cells 
in the ventral lateral endoderm of the foregut (Figures 3B’, C’ and D’, arrows), whereas, no 
proliferating cells were found in the ventral midline (Figures 3B’, C’ and D’, arrowhead). 
Between stage 8
-
 and 10
-
, proliferating cells still existed in the entire ventral lateral endoderm 
(Figures 4B’, C’, D’ and E’, arrows). Also, area without proliferating cells was restricted in the 
middle and posterior part of the ventral midline (Figures 4B’, C’, D’ and E’, arrowhead). 
Between stage 9 and 11
+
, in the ventral midline proliferating cell was not detected only at 
posterior part (Figures 5B’, C’ and D’, arrowhead). Between stage 10+ and 12-, in whole 
ventral midline proliferating cells were detected (Figures 6B’, C’ and D’, arrowhead). However, 
a proliferating rate in the ventral midline was lower than in lateral region (Figures 6B’, C’ and 
D’, arrows).  
Between stage 7 and 9, despite of rapid extension of the ventral midline cells in the 
foregut, those cells did not proliferate at all. Therefore, it is suggested that the ventral midline 
extension is caused by rearrangement of the midline cells in AIP, but not by proliferation. 
Interestingly, these non-proliferating areas in the ventral midline restricted posteriorly as the 
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foregut formed. This is consistent with the result that the midline endodermal cells in AIP 
extend only in the posterior ventral midline as formation of the foregut occurs (Figure 1).  
 
 
Full-length CDS of Glypican-3 was cloned from 3-day-old chicken embryo. 
In this study it is revealed that cell rearrangement, not cell proliferation in the ventral 
midline cells was involved in the elongation of the foregut and those cells rearrangement end 
gradually from anterior. This means the ventral midline of the foregut is important not only for 
generation of the many organ primordia from the foregut, but also for foregut formation itself. 
Now, to investigate molecular mechanisms of the differentiation of the ventral midline in the 
foregut, I picked up Glypican-3, which is expressed in the ventral foregut (Kimura et al., 2011). 
Glypican-3 is known to regulate many signaling pathways, like Wnt, BMP, FGF and Shh 
(Capurro et al., 2014, Grisaru et al., 2001, Capurro et al., 2008). 
Full-length CDS of chicken Glypican-3 was not identified yet so firstly, I cloned and 
sequenced it. Primers for PCR were designed by referring to the predicted sequence of 
Glypican-3 in NCBI; accession number XM_001232891.3 (Figure 7A). cDNA from 3-day-old 
chicken embryos was used as template for RT-PCR, and a PCR product of about 1,850-bp in 
length was obtained (Figures 7A and B). To confirm whether this PCR product includes 
Glypican-3, nested PCR was carried out. In the nested PCR, estimated length of products is 
about 990-bp in length and I got product as the same length. (Figures 7A and C). The first PCR 
product was cloned, and 3 clones which contained insert of 2,000-bp in length (Figures 7D) 
were analyzed. By treatment of a restriction enzyme, SacI, plasmids purified from each clone 
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were divided into 1,450-bp and 3,550-bp in length as estimated so it is confirmed that these 
plasmids included Glypican-3 (Figures 7E and F). After analysis of sequence, it was revealed 
that two clones had sequence almost the same as those of predicted Glypican-3 in NCBI 
database (clone 1 and 2) and one clone lacked exon 7 (clone 3). Some single nucleotide 
differences were detected in each clone (Figure 8). Variant Glypican-3 cDNA lacking exon 7 
lost GPI anchor signal sequence and heparan sulfate glycosylation signal sequence due to a 
frameshift (hereinafter referred to as ΔGlypican-3). Another PCR using cDNA from 2 and 
3-day-old embryos as template with specific primers for exon 6 and 8 revealed that no 
ΔGlypican-3 was detected (Figure 7G) so it is suggested that ΔGlypican-3 is infinitesimal or 
miss-spliced product. 
 
 
Glypican-3 was expressed in the ventral midline endoderm of the foregut. 
DIG-RNA Probes for Glypican-3 were synthesized to observe the expression pattern 
of Glypican-3 in detail by WISH. At stage 3 and 4, Glypican-3 was expressed in the anterior 
extraembryonic endoderm (Figures 9A, B and B’, arrowhead). At stage 5, Glypican-3 was 
expressed in the anterior endoderm (Figure 9C arrowhead and C’) and the lateral ectoderm of 
the primitive streak (Figure 9C, arrows and C’’). At stage 6, the expression of Glypican-3 in 
the anterior endoderm spread around the head fold (Figure 9D and D’, arrowhead). At stage 
7-8
+
, Glypican-3 was expressed in the ventral foregut widely (Figures 10A, B, and 11A, B). 
Glypican-3 expression was stronger toward the midline (Figures 10A and 11A) and posterior 
part of the ventral foregut (Figures 10B and 11B). At stage 9-10, Glypican-3 expression was 
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restricted to the ventral midline in the middle to posterior part of the foregut (Figures 12 and 
13). At stage 10
+
-11, Glypican-3 expression in the posterior ventral midline weakened and 
restricted to those in the middle part (Figures 14 and 15A). At stage 14 and 16, Glypican-3 
expression was restricted to the thyroid, the lung and the liver endoderm (Figures 15B and 16A, 
arrowheads). At stage 18, Glypican-3 was also expressed at the hindgut and the limb bud 
(Figure 16B, arrowheads). The strongest expression of Glypican-3 was found in the ventral 
midline endoderm of the foregut, and the gradient of Glypican-3 expression was detected along 
the anteroposterior and mediolateral axis during foregut elongation and specification. After 
specification, Glypican-3 was expressed in the thyroid, the lung and the liver endoderm, which 
will develop each organ primordia. 
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Discussion 
 
Various organs such as thyroid, lung, esophagus, stomach, liver and pancreas develop 
from the foregut endoderm. Thus, foregut formation is important for the digestive tract 
development, and also patterning of anterior neural tissue and development of heart in the 
chicken embryo (Withington et al., 2001). Therefore it is important to understand the 
mechanisms of the foregut formation in order to know whole anterior embryogenesis. It was 
suggested in the report by Kirby et al., 2003 and Withington at al., 2001 that the midline cells 
in AIP are important for the foregut elongation in stage 7. 
In the present thesis, the fate of the midline cells in AIP was analyzed at the various 
stages. At the beginning of rapid elongation of the foregut (stage 7) the midline cells in AIP 
spread into whole ventral midline anteroposteriorly (Figure 1A and B), whereas after the rapid 
elongation (stage 10) AIP midline cells stayed at AIP and no expansion was observed (Figures 
1G-L). These results are apparent evidence to consider the function of AIP for elongation of 
the foregut. The expansion of AIP midline cells might be a driving force for rapid foregut 
elongation. Also, expansion area of AIP midline cells gradually became narrower towards 
posteriorly as the foregut formation progressed (Figure 1A-F). These findings suggest that the 
ventral foregut elongation by extension of the ventral midline is completed from anterior to 
posterior gradually. It is therefore possible that speed of rapid foregut extension were getting 
decrease as the foregut formation. Between stage 7 and 10, somites were formed clockwise, 
every 90 minutes, so I can measure the foregut length in each somite stages to confirm this 
hypothesis. 
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Next, proliferating ventral midline cells were detected by BrdU treatment between 
stage 6, before the foregut formation, and 8 (Figures 2B, C and D), but no proliferating cells 
were found in the ventral midline between stage 7 and 9, after initiation of the foregut 
elongation (Figures 3B’, C’ and D’, arrowhead). These results indicate that the ventral midline 
endodermal cells in the foregut show no proliferation during extension and those endodermal 
cells, which contribute to the ventral midline, proliferate before stage 7 (Figure 17, panel A and 
B). As mentioned in the previous section, the ventral midline cells were provided from AIP. It 
is suggested that endodermal cells which contribute to the ventral midline proliferate and are 
stocked in AIP before the foregut elongation in order to supply the sufficient number of cells 
for the ventral midline during the foregut elongation.  
Interestingly, non-proliferating area in the ventral midline became restricted 
posteriorly as the foregut developed (Figures 3, 4 and 5). This consistency between 
non-proliferating area and expanding area from AIP in the ventral midline suggested that the 
ventral midline in the foregut extends rapidly by only cell rearrangement from AIP (Figure 17, 
panel B). During the foregut elongation, foregut changes narrower and longer (Bellairs, 1953a 
and 1953b). Kirby et al., 2003 shows when both side of AIP in stage 7 were labeled, both 
labeled cells were found near the ventral midline in stage 10. Also, in this thesis when midline 
of AIP was labeled, labeled cells were expanded into the ventral midline with salt-and-paper 
pattern (Figures 1A and B). Taken together, cell arrangement of ventral midline occurs by 
convergent and extension movement. 
After rapid extension of ventral in the foregut, the foregut continues to elongate as 
same speed as body growth (slow elongation) from about stage 10. Between stage 10
+
 and 12
-
, 
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there was no extension of the ventral midline of AIP, a few endodermal cells in the ventral 
midline of the foregut proliferated again (Figure 6). I suggest that this proliferation supports 
slow elongation of the foregut or organ formation describe next section (Figure 17, panel C).  
Following the foregut elongation, the organ specification and differentiation occur in 
the foregut endoderm. Before formation of organ primordia, each endoderm was regionalized 
and already expressed specific marker genes localized along the ventral midline. The 
expression of these genes is controlled by several signaling pathways. For example, BMP 
signaling from the septum transversum and FGF signaling from the cardiac mesoderm is 
necessary for maintenance of Hex expression in the ventral foregut endoderm and hepatocyte 
differentiation (Zhang et al., 2004, Duncan et al., 2001). I suggest that only when the cell 
rearrangement from AIP complete, endodermal cells can be regionalized depending on their 
position in the foregut because cells stay at the same position to receive certain signaling 
continuously. 
In the above experiments, I revealed the interesting character of the ventral foregut 
midline endoderm providing the foregut elongation. Also, the ventral midline in the foregut is 
specified for various regions to produce each organ primordium. On the other hand, the 
molecular mechanism to control cell proliferation, rearrangement and specification in the 
ventral midline of the foregut is still unknown. The previous study demonstrated that 
Glypican-3 was expressed in the ventral foregut (Kimura et al., 2011). I was interested in the 
function of Glypican-3 in the ventral foregut. It has been reported that Glypican-3 regulates 
Wnt, BMP, FGF and Shh signaling (Capurro et al., 2014, Grisaru et al., 2001, Capurro et al., 
2008) and also is involved in regulation of cell viability and proliferation (Cai et al., 2017). In 
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this thesis I isolated full-length CDS of Glypican-3 and analyzed its expression pattern during 
the foregut formation. Glypican-3 was expressed in the anterior endoderm, which is 
presumptive foregut endoderm at stage 5 and 6 (Figures 9A and B), and strongly in the ventral 
midline endoderm of the foregut from stage 7 to 10 (Figures 10-13). From this expression 
pattern, Glypican-3 may be involved in the cell rearrangement or proliferation of the ventral 
midline from AIP.  
At stage 9-11
-
, expression of Glypican-3 was detected especially remarkable in the 
ventral midline (Figures 12, 13 and 14). At these stages, the ventral midline became thickened 
than ventral side region. It is possible that Glypican-3 may control the change of cell shape in 
the ventral midline at this stage. 
After stage 11 expression of Glypican-3 in the ventral midline starts to be restricted 
into three regions, presumptive thyroid, lung and liver region. Then from stage 14 its 
expression was restricted clearly in those organ primordia (Figures 15 and 16). There is a 
possibility that Glypican-3 controls also organ differentiation. 
To prove above hypothesis of the function of Glypican-3, loss-of-function 
experiments using siRNA introduce into the ventral midline is required. 
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Figure 1. DiI-labeled midline endodermal cells of AIP up to stage 9 expanded into the ventral 
midline. 
 
(A and B) Some DiI-labeled midline endodermal cells of AIP at stage 7
+
 spread widely into the 
ventral midline along with anterior-posterior axis at stage 11. (C and D) Some DiI-labeled 
midline endodermal cells of AIP at stage 9 spread into the middle and posterior part of the 
ventral midline at stage 12. (E and F) Some DiI-labeled midline endodermal cells of AIP at 
stage 10 expanded slightly at the posterior part of the ventral midline at stage 11. (G, I and K) 
Some midline endodermal cells of AIP at stage 11, 12 and 13 were labeled with DiI. (H, J and 
L) Cells labelled at stage 11, 12 and 13 (G, I and K) showed no movement or expansion and 
kept their position at AIP in stage 14, 15 and 14 respectively. Scale bars =500µm. 
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Figure 2. The proliferating cells were observed in the whole foregut endoderm between stage 6 
and 8. 
 
(A) Bright field image of embryo at stage 8. (B, C and D) Transverse sections stained by DAPI 
(cyan) and anti BrdU antibody (magenta) through the embryo in panel A. (B’, C’ and D’) High 
magnified images in the lateral area of B, C and D respectively. Arrowheads indicate the 
ventral midline. (B’’, C’’ and D’’) High magnified images in the ventral midline area of B, C 
and D respectively. Scale bar =200µm. 
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Figure 3. No proliferating cells were found in the ventral midline of the foregut endoderm 
between stage 7 and 9. 
 
(A) Bright field image of embryo at stage 9. (B, C and D) Transverse sections stained by DAPI 
(cyan) and anti BrdU antibody (magenta) through the embryo in panel A. (B’, C’ and D’) High 
magnified images in the ventral midline area of B, C and D respectively. Arrowheads indicate 
the ventral midline. Arrows indicate proliferating cells in the ventral lateral endoderm. Scale 
bar =200µm. 
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Figure 4. Proliferating cell was not detected in the middle and posterior part of the ventral 
midline of the foregut endoderm between stage 8
-
 and 10
-
. 
 
(A) Bright field image of embryo at stage 10
-
. (B, C and D) Transverse sections stained by 
DAPI (cyan) and anti BrdU antibody (magenta) through the embryo in panel A. (B’, C’, D’ and 
E’) High magnified images in the ventral midline area of B, C, D and E respectively. 
Arrowheads indicate the ventral midline. Arrows indicate proliferating cells in the ventral 
lateral endoderm. Scale bar =200µm. 
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Figure 5. Proliferating cell was not detected at the posterior region of ventral midline of the 
foregut endoderm between stage 9 and 11
+
. 
 
(A) Bright field image of embryo at stage 11
+
. (B, C and D) Transverse sections stained by 
DAPI (cyan) and anti BrdU antibody (magenta) through the embryo in panel A. (B’, C’ and 
D’) High magnified images in the ventral midline area of B, C and D respectively. Arrowheads 
indicate the ventral midline. Scale bar =200µm. 
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Figure 6. Proliferating cells were detected in whole ventral midline of the foregut between 
stage 10
+
 and 12
-
. 
 
(A) Bright field image of embryo at stage 12
-
. (B, C and D) Transverse sections stained by 
DAPI (cyan) and anti BrdU antibody (magenta) through the embryo in panel A. (B’, C’ and 
D’) High magnified images in the ventral midline area of B, C and D respectively. Arrowheads 
indicate the ventral midline. Arrows indicate proliferating cells in the ventral lateral endoderm. 
Scale bar =200µm. 
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Figure 7. The process of full-length CDS cloning of Glypican-3 from 3-day-old chicken 
embryo. 
 
(A) The schematic figure of primers design of RT-PCR and nested PCR. (B) PCR product of 
about 1,850-bp in length was obtained by RT-PCR. (C) PCR product of about 990-bp in length 
was obtained by nested PCR. (D) Three clones containing insert of 2,000-bp in length were 
obtained by TA cloning. (E) The schematic figure of restriction experiment. (F) Plasmids 
purified from each clone were divided into 1,450-bp and 3,550-bp in length by restriction 
reaction. (G) Lane 1: PCR product of about 530-bp in length amplified from the plasmid of 
Glypican-3. Lane 2: PCR product of about 380-bp in length amplified from the plasmid of 
ΔGlypican-3. Lane 3: PCR product of about 530-bp in length amplified from a cDNA of 
3-day-old embryo. 
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Figure 8. Nucleotide and amino acid sequences of each clone of Glypican-3. 
 
(A) Nucleotide and amino acid sequences of clone 1. The CDS consists of 1,731 nucleotides 
and encodes 576 amino acids. (B) Nucleotide and amino acid sequences of clone 2. The CDS 
consists of 1,731 nucleotides and encodes 576 amino acids. (C) Nucleotide and amino acid 
sequences of clone 3. The CDS consists of 1,458 nucleotides and encodes 485 amino acids. 
Clone 3 lacked exon 7. Single nucleotide differences among the clones were written in red. 
Amino acid difference among the clones was indicated by underline. 
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A, Nucleotide and amino acid sequences of clone 1. 
 
 
  ATG TCG GGG AGC GGC GGA GCG TCG CCG CCG TCG GTG CTG TTT CTG CTG CTC CTG GCG GCC CCG GGG TTC GCC   72 
   M   S   G   S   G   G   A   S   P   P   S   V   L   F   L   L   L   L   A   A   P   G   F   A    24 
 
   
  CAA CCG GCG GGG GAG GCC GCC TGC CGC CCG GTC CGA GCC GCT TTC CAG GTG CTG CAG CCC GGA GCC AAG TGG   144 
   Q   P   A   G   E   A   A   C   R   P   V   R   A   A   F   Q   V   L   Q   P   G   A   K   W     48 
 
   
  GTG CCC GAG AGC CCC GTG CCA GGG TTG GAC CTG CAG GTA TGC ATC CCC AAG GGC TCC ACG TGC TGC TCG AGG   216 
   V   P   E   S   P   V   P   G   L   D   L   Q   V   C   I   P   K   G   S   T   C   C   S   R     72 
 
   
  AGG ATG GAG GAG AAG TAC CAG GCA GTG GCC CGG CAG AAC ATG GAG CAG CTC CTG CAG TCT GCC AGC ATG GAG   288 
   R   M   E   E   K   Y   Q   A   V   A   R   Q   N   M   E   Q   L   L   Q   S   A   S   M   E     96 
 
   
  CTG AAG TTC CTT GTC ATC CAG AAT GCT GCT GTC TTC CAA GAA GCC TTT GAG ATT GTA GTG CGG CAC GCG AGG   360 
   L   K   F   L   V   I   Q   N   A   A   V   F   Q   E   A   F   E   I   V   V   R   H   A   R    120 
 
   
  AAC TTC ACC AAC AGC ATG TTT AGG AGC CAC TAC AAG AGC ATG GGG CCC AGA GCT CTT AAG TTT GTT GGA GAA   432 
   N   F   T   N   S   M   F   R   S   H   Y   K   S   M   G   P   R   A   L   K   F   V   G   E    144 
 
   
  CTT TTC ACG GAT GTC TCG CTG TAC ATA CTG GGC TCT GAC ATC AGC GTT AAT GAC ATG ATA AAT GAA TTT TTT   504 
   L   F   T   D   V   S   L   Y   I   L   G   S   D   I   S   V   N   D   M   I   N   E   F   F    168 
 
   
  GAT AGT TTA TTT CCT TTG GTC TAC TCC CAC TTG ATC AAT CCC GGC TTC CCG GAT CCC TCA GTG GAA ATG ACT   576 
   D   S   L   F   P   L   V   Y   S   H   L   I   N   P   G   F   P   D   P   S   V   E   M   T    192 
 
   
  GAA TGC CTG CGG GCA GCC AGG AGA GAC CTC AAG GCC TTT GGT AAC TAC CCG AAG ATG ATG ATG ACG CAG GTG   648 
   E   C   L   R   A   A   R   R   D   L   K   A   F   G   N   Y   P   K   M   M   M   T   Q   V    216 
 
   
  TCC AAG TCG CTG CAG GCC ACG CGG GTC TTT CTG CAG GCA CTC AAC CTG GGG ATC GAG GTG ATA AAC ACC ACC   720 
   S   K   S   L   Q   A   T   R   V   F   L   Q   A   L   N   L   G   I   E   V   I   N   T   T    240 
 
   
  GAC CAC CTG AAG CTC AGC AAG GAG TGC GGG CGG GCG CTG CTC AAG ATG TGG TAC TGC TCA CAC TGC CAG GGG   792 
   D   H   L   K   L   S   K   E   C   G   R   A   L   L   K   M   W   Y   C   S   H   C   Q   G    264 
 
   
  CTG CTG CTG GCC AAG CCC TGT GCT GGG TAC TGC GGT GTG GTG ACA TAC GGG TGC CTG GCA GGG GTT GGT GAG   864 
   L   L   L   A   K   P   C   A   G   Y   C   G   V   V   T   Y   G   C   L   A   G   V   G   E    288 
 
   
  ATC GAC CGT CAC TGG AGA GAT TAT ATC AGC TCC TTG GAG GGG TTG ACC AAG GGC ATG CGT GGT GTC TAT GAC   936 
   I   D   R   H   W   R   D   Y   I   S   S   L   E   G   L   T   K   G   M   R   G   V   Y   D    312 
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  ATG GAG CAC GTC CTC CTG AAC CTC TTC TCC CTG GTG AGG GAT GCC GTC ATC TAC GTG CAG AAG AAT GGA GGA   1008 
   M   E   H   V   L   L   N   L   F   S   L   V   R   D   A   V   I   Y   V   Q   K   N   G   G    336 
 
   
  AAG CTC TCG GCA ACT GTC AGC AGG CTC TGC GGT CAC GCT CAG CAG AGG CAG TAT CGA TCC ACT AAT TAC CCC   1080 
   K   L   S   A   T   V   S   R   L   C   G   H   A   Q   Q   R   Q   Y   R   S   T   N   Y   P    360 
 
   
  GAA GAC CTC TTC ATT GAC AAA AAA GGC CTG AAG GTG ACT CAC ATA GAG CAG GAA GAA ACG CTG TCG AGC AGG   1152 
   E   D   L   F   I   D   K   K   G   L   K   V   T   H   I   E   Q   E   E   T   L   S   S   R    384 
 
   
  AGG AGG GAA CTG ATT ACG AAG CTG AAG TCT CAC AGT GAT TTT TAC AGC ACC TTG CCA GAG TAC ATC TGC AAC   1224 
   R   R   E   L   I   T   K   L   K   S   H   S   D   F   Y   S   T   L   P   E   Y   I   C   N    408 
 
   
  CAC AGC TCT GCT GTT CAG AAT GAC ACC GTT TGC TGG AAC GGG CAA GAA GTC GTG GAG AGG TAC AGT CCC CAC   1296 
   H   S   S   A   V   Q   N   D   T   V   C   W   N   G   Q   E   V   V   E   R   Y   S   P   H    432 
 
   
  ATC CCA AGG AAT GGA GCA AAA GCT CAG CCT GGT AAC CAT GAA GGG AAG ATG AAA GGT CCT GAG CCA GTG ATC   1368 
   I   P   R   N   G   A   K   A   Q   P   G   N   H   E   G   K   M   K   G   P   E   P   V   I    456 
 
   
  AGC CAG ATC ATT GAC AAG CTG AAA CAC ATC AAC CAG CTG CTC AAA GGG ATG GCT TTG CCC CAC CGA AGA GCT   1440 
   S   Q   I   I   D   K   L   K   H   I   N   Q   L   L   K   G   M   A   L   P   H   R   R   A    480 
 
   
  ACA GGC AAA ACC CCA GAG GAG GAG GAA GAG GAG AGC GGA GAC TGC GAT GAT GAA GAT GAC TGT GGC AGA GGC   1512 
   T   G   K   T   P   E   E   E   E   E   E   S   G   D   C   D   D   E   D   D   C   G   R   G    504 
 
   
  TCT GGG GAT GGA GAG CTG CGA GTG AGG AAC CAG CTC CGG TTC TTA GCA GAG CTG TCG TAC GAC CTG GAC GTG   1584 
   S   G   D   G   E   L   R   V   R   N   Q   L   R   F   L   A   E   L   S   Y   D   L   D   V    528 
 
   
  GAT GAC ACC TCA GCC AAC AAG CAG CTG TTG AAC CAG CAC AAC AAG GAT GGG GCC GCT GTG CCC AGC ACT GAT   1656 
   D   D   T   S   A   N   K   Q   L   L   N   Q   H   N   K   D   G   A   A   V   P   S   T   D    552 
 
   
  CCC AGC AGT GCA GCC CCA CGC CTT GGC CCT ACT GCT GCC ATC ACC TTA GCC CTG CTG CTG GGC TGC TGG CCC   1728 
   P   S   S   A   A   P   R   L   G   P   T   A   A   I   T   L   A   L   L   L   G   C   W   P    576 
 
   
  TGA   1731 
   *    
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B, Nucleotide and amino acid sequences of clone 2. 
 
 
  ATG TCG GGG AGC GGC GGA GCG TCG CCG CCG TCG GTG CTG TTT CTG CTG CTC CTG GCG GCC CCG GGG TTC GCC   72 
   M   S   G   S   G   G   A   S   P   P   S   V   L   F   L   L   L   L   A   A   P   G   F   A    24 
 
   
  CAA CCG GCG GGG GAG GCC GCC TGC CGC CCG GTC CGA GCC GCT TTC CAG GTG CTG CAG CCC GGA GCC AAG TGG   144 
   Q   P   A   G   E   A   A   C   R   P   V   R   A   A   F   Q   V   L   Q   P   G   A   K   W     48 
 
   
  GTG CCC GAG AGC CCC GTG CCA GGG TTG GAC CTG CAG GTA TGC ATC CCC AAG GGC TCC ACG TGC TGC TCG AGG   216 
   V   P   E   S   P   V   P   G   L   D   L   Q   V   C   I   P   K   G   S   T   C   C   S   R     72 
 
   
  AGG ATG GAG GAG AAG TAC CAG GCA GTG GCC CGG CAG AAC ATG GAG CAG CTC CTG CAG TCT GCC AGC ATG GAG   288 
   R   M   E   E   K   Y   Q   A   V   A   R   Q   N   M   E   Q   L   L   Q   S   A   S   M   E     96 
 
   
  CTG AAG TTC CTT GTC ATC CAG AAT GCT GCT GTC TTC CAA GAA GCC TTT GAG ATT GTA GTG CGG CAC GCG AGG   360 
   L   K   F   L   V   I   Q   N   A   A   V   F   Q   E   A   F   E   I   V   V   R   H   A   R    120 
 
   
  AAC TTC ACC AAC AGC ATG TTT AGG AGC CAC TAC AAG AGC ATG GGG CCC AGA GCT CTT AAG TTT GTT GGA GAA   432 
   N   F   T   N   S   M   F   R   S   H   Y   K   S   M   G   P   R   A   L   K   F   V   G   E    144 
 
   
  CTT TTC ACG GAT GTC TCG CTG TAC ATA CTG GGC TCT GAC ATC AGC GTT AAT GAC ATG ATA AAT GAA TTT TTT   504 
   L   F   T   D   V   S   L   Y   I   L   G   S   D   I   S   V   N   D   M   I   N   E   F   F    168 
 
   
  GAT AGT TTA TTT CCT TTG GTC TAC TCC CAC TTG ATC AAT CCC GGC TTC CCG GAT CCC TCA GTG GAA ATG ACT   576 
   D   S   L   F   P   L   V   Y   S   H   L   I   N   P   G   F   P   D   P   S   V   E   M   T    192 
 
   
  GAA TGC CTG CGG GCA GCC AGG AGA GAC CTC AAG GCC TTT GGT AAC TAC CCG AAG ATG ATG ATG ACG CAG GTG   648 
   E   C   L   R   A   A   R   R   D   L   K   A   F   G   N   Y   P   K   M   M   M   T   Q   V    216 
 
   
  TCC AAG TCG CTG CAG GCC ACG CGG GTC TTT CTG CAG GCA CTC AAC CTG GGG ATC GAG GTG ATA AAC ACC ACC   720 
   S   K   S   L   Q   A   T   R   V   F   L   Q   A   L   N   L   G   I   E   V   I   N   T   T    240 
 
   
  GAC CAC CTG AAG CTC AGC AAG GAG TGC GGG CGG GCG CTG CTC AAG ATG TGG TAC TGC TCA CAC TGC CAG GGG   792 
   D   H   L   K   L   S   K   E   C   G   R   A   L   L   K   M   W   Y   C   S   H   C   Q   G    264 
 
   
  CTG CTG CTG GCC AAG CCC TGT GCT GGG TAC TGC GGT GTG GTG ACA TAC GGG TGC CTG GCA GGG GTT GGT GAG   864 
   L   L   L   A   K   P   C   A   G   Y   C   G   V   V   T   Y   G   C   L   A   G   V   G   E    288 
 
   
  ATC GAC CGT CAC TGG AGA GAT TAT ATC AGC TCC TTG GAG GGG TTG ACC AAG GGC ATG CGT GGT GTC TAT GAC   936 
   I   D   R   H   W   R   D   Y   I   S   S   L   E   G   L   T   K   G   M   R   G   V   Y   D    312 
 
 40 
 
  ATG GAG CAC GTC CTC CTG AAC CTC TTC TCC CTG GTG AGG GAT GCC GTC ATC TAC GTG CAG AAG AAT GGA GGA   1008 
   M   E   H   V   L   L   N   L   F   S   L   V   R   D   A   V   I   Y   V   Q   K   N   G   G    336 
 
   
  AAG CTC TCG GCA ACT GTC AGC AGG CTC TGC GGT CAC GCT CAG CAG AGG CAG TAT CGA TCC ACT AAT TAC CCC   1080 
   K   L   S   A   T   V   S   R   L   C   G   H   A   Q   Q   R   Q   Y   R   S   T   N   Y   P    360 
 
   
  GAA GAC CTC TTC ATT GAC AAA AAA GGC CTG AAG GTG ACT CAC ATA GAG CAG GAA GAA ACG CTG TCG AGC AGG   1152 
   E   D   L   F   I   D   K   K   G   L   K   V   T   H   I   E   Q   E   E   T   L   S   S   R    384 
 
   
  AGG AGG GAA CTG ATT ACG AAG CTG AAG TCT CAC AGT GAT TTT TAC AGC ACC TTG CCA GAG TAC ATC TGC AAC   1224 
   R   R   E   L   I   T   K   L   K   S   H   S   D   F   Y   S   T   L   P   E   Y   I   C   N    408 
 
   
  CAC AGC TCT GCT GTT CAG AAT GAC ACC GTT TGC TGG AAC GGG CAA GAA GTC GTG GAG AGG TAC AGT CCC CAC   1296 
   H   S   S   A   V   Q   N   D   T   V   C   W   N   G   Q   E   V   V   E   R   Y   S   P   H    432 
 
   
  ATC CCA AGG AAT GGA GCA AAA GCT CAG CCT GGT AAC CAT GAG GGG AAG ATG AAA GGT CCT GAG CCA GTG ATC   1368 
   I   P   R   N   G   A   K   A   Q   P   G   N   H   E   G   K   M   K   G   P   E   P   V   I    456 
 
   
  AGC CAG ATC ATT GAC AAG CTG AAA CAC ATC AAC CAG CTG CTC AAA GGG ATG GCT TTG CCC CAC CGA AGA GCT   1440 
   S   Q   I   I   D   K   L   K   H   I   N   Q   L   L   K   G   M   A   L   P   H   R   R   A    480 
 
   
  ACA GGC AAA ACC CCA GAG GAG GAG GAA GAG GAG AGC GGA GAC TGC GAT GAT GAA GAT GAC TGT GGC AGA GGC   1512 
   T   G   K   T   P   E   E   E   E   E   E   S   G   D   C   D   D   E   D   D   C   G   R   G    504 
 
   
  TCT GGG GAT GGA GAG CTG CGA GTG AGG AAC CAG CTC CGG TTC TTA GCA GAG CTG TCG TAC GAC CTG GAC GTG   1584 
   S   G   D   G   E   L   R   V   R   N   Q   L   R   F   L   A   E   L   S   Y   D   L   D   V    528 
 
   
  GAT GAC ACC TCA GCC AAC AAG CAG CTG TTG AAC CAG CAC AAC AAG GAT GGG GCC GCT GTG CCC AGC ACT GAT   1656 
   D   D   T   S   A   N   K   Q   L   L   N   Q   H   N   K   D   G   A   A   V   P   S   T   D    552 
 
   
  CCC AGC AGT GCA GCC CCA CGC CTT GGC CCT ACT GCT GCC ATC ACC TTA GCC CTG CTG CTG GGC TGC TGG CCC   1728 
   P   S   S   A   A   P   R   L   G   P   T   A   A   I   T   L   A   L   L   L   G   C   W   P    576 
 
   
  TGA   1731 
   *    
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C, Nucleotide and amino acid sequences of clone 3. 
 
 
  ATG TCG GGG AGC GGC GGA GCG TCG CCG CCG TCG GTG CTG TTT CTG CTG CTC CTG GCG GCC CCG GGG TTC GCC   72 
   M   S   G   S   G   G   A   S   P   P   S   V   L   F   L   L   L   L   A   A   P   G   F   A    24 
 
   
  CAA CCG GCG GGG GAG GCC GCC TGC CGC CCG GTC CGA GCC GCT TTC CAG GTG CTG CAG CCC GGA GCC AAG TGG   144 
   Q   P   A   G   E   A   A   C   R   P   V   R   A   A   F   Q   V   L   Q   P   G   A   K   W     48 
 
   
  GTG CCC GAG AGC CCC GTG CCA GGG TTG GAC CTG CAG GTA TGC ATC CCC AAG GGC TCC ACG TGC TGC TCG AGG   216 
   V   P   E   S   P   V   P   G   L   D   L   Q   V   C   I   P   K   G   S   T   C   C   S   R     72 
 
   
  AGG ATG GAG GAG AAG TAC CAG GCA GTG GCC CGG CAG AAC ATG GAG CAG CTC CTG CAG TCT GCC AGC ATG GAG   288 
   R   M   E   E   K   Y   Q   A   V   A   R   Q   N   M   E   Q   L   L   Q   S   A   S   M   E     96 
 
   
  CTG AAG TTC CTT GTC ATC CAG AAT GCT GCT GTC TTC CAA GAA GCC TTT GAG ATT GTA GTG CGG CAC GCG AGG   360 
   L   K   F   L   V   I   Q   N   A   A   V   F   Q   E   A   F   E   I   V   V   R   H   A   R    120 
 
   
  AAC TTC ACC AAC AGC ATG TTT AGG AGC CAC TAC AAG AGC ATG GGG CCC AGA GCT CTT AAG TTT GTT GGA GAA   432 
   N   F   T   N   S   M   F   R   S   H   Y   K   S   M   G   P   R   A   L   K   F   V   G   E    144 
 
   
  CTT TTC ACG GAT GTC TCG CTG TAC ATA CTG GGC TCT GAC ATC AGC GTT AAT GAC ATG ATA AAT GAA TTT TTT   504 
   L   F   T   D   V   S   L   Y   I   L   G   S   D   I   S   V   N   D   M   I   N   E   F   F    168 
 
   
  GAT AGT TTA TTT CCT TTG GTC TAC TCC CAC TTG ATC AAT CCC GGC TTC CCG GAT CCC TCA GTG GAA ATG ACT   576 
   D   S   L   F   P   L   V   Y   S   H   L   I   N   P   G   F   P   D   P   S   V   E   M   T    192 
 
   
  GAA TGC CTG CGG GCA GCC AGG AGA GAC CTC AAG GCC TTT GGT AAC TAC CCG AAG ATG ATG ATG ACG CAG GTG   648 
   E   C   L   R   A   A   R   R   D   L   K   A   F   G   N   Y   P   K   M   M   M   T   Q   V    216 
 
   
  TCC AAG TCG CTG CAG GCC ACG CGG GTC TTT CTG CAG GCA CTC AAC CTG GGG ATC GAG GTG ATA AAC ACC ACC   720 
   S   K   S   L   Q   A   T   R   V   F   L   Q   A   L   N   L   G   I   E   V   I   N   T   T    240 
 
   
  GAC CAC CTG AAG CTC AGC AAG GAG TGC GGG CGG GCG CTG CTC AAG ATG TGG TAC TGC TCA CAC TGC CAG GGG   792 
   D   H   L   K   L   S   K   E   C   G   R   A   L   L   K   M   W   Y   C   S   H   C   Q   G    264 
 
   
  CTG CTG CTG GCC AAG CCC TGT GCT GGG TAC TGC GGT GCG GTG ACG TAC GGG TGC CTG GCA GGG GTT GGT GAG   864 
   L   L   L   A   K   P   C   A   G   Y   C   G   V   V   T   Y   G   C   L   A   G   V   G   E    288 
 
   
  ATC GAC CGT CAC TGG AGA GAT TAT ATC AGC TCC TTG GAG GGG TTG ACC AAG GGT ATG CGT GGT GTC TAT GAC   936 
   I   D   R   H   W   R   D   Y   I   S   S   L   E   G   L   T   K   G   M   R   G   V   Y   D    312 
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  ATG GAG CAC GTC CTC CTG AAC CTC TTC TCC CTG GTG AGG GAT GCC GTC ATC TAC GTG CAG AAG AAT GGA GGA   1008 
   M   E   H   V   L   L   N   L   F   S   L   V   R   D   A   V   I   Y   V   Q   K   N   G   G    336 
 
   
  AAG CTC TCG GCA ACT GTC AGC AGG CTC TGC GGT CAC GCT CAG CAG AGG CAG TAT CGA TCC ACT AAT TAC CCC   1080 
   K   L   S   A   T   V   S   R   L   C   G   H   A   Q   Q   R   Q   Y   R   S   T   N   Y   P    360 
 
   
  GAA GAC CTC TTC ATT GAC AAA AAA GGC CTG AAG GTG ACT CAC ATA GAG CAG GAA GAA ACG CTG TCG AGC AGG   1152 
   E   D   L   F   I   D   K   K   G   L   K   V   T   H   I   E   Q   E   E   T   L   S   S   R    384 
 
   
  AGG AGG GAA CTG ATT ACG AAG CTG AAG TCT CAC AGT GAT TTT TAC AGC ACC TTG CCA GAG TAC ATC TGC AAC   1224 
   R   R   E   L   I   T   K   L   K   S   H   S   D   F   Y   S   T   L   P   E   Y   I   C   N    408 
 
   
  CAC AGC TCT GCT GTT CAG AAT GAC ACC GTT TGC TGG AAC GGG CAA GAA GTC GTG GAG AGG TAC AGT CCC CAC   1296 
   H   S   S   A   V   Q   N   D   T   V   C   W   N   G   Q   E   V   V   E   R   Y   S   P   H    432 
 
   
  ATC CCA AGG AAT GGA GCA AAA GCT CAG CCT GGT AAC CAT GAA GGG AAG ATG AAA GGT CCT GAG CCA GTG ATC   1368 
   I   P   R   N   G   A   K   A   Q   P   G   N   H   E   G   K   M   K   G   P   E   P   V   I    456 
 
   
  AGC CAG ATC ATT GAC AAG CTG AAA CAC ATC AAC CAG AGC TGT CGT ACG ACC TGG ACG TGG ATG ACA CCT CAG   1440 
   S   Q   I   I   D   K   L   K   H   I   N   Q   S   C   R   T   T   W   T   W   M   T   P   Q    480 
 
 
  CCA ACA AGC AGC TGT TGA   1458 
   P   T   S   S   C   *    485 
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Figure 9. The expression pattern of Glypican-3 at stage 3, 4, 5 and 6 chick embryo. 
 
(A) WISH of Glypican-3 at stage 3. (B) WISH of Glypican-3 at stage 4. (B’) Transverse 
section through the embryo in panel B. Arrowhead indicates the signal in the anterior 
extraembryonic endoderm. (C) WISH of Glypican-3 at stage 5. Arrowhead indicates the signal 
in the anterior endoderm. Arrows indicate the signal in the lateral ectoderm of the primitive 
streak. (C’ and C’’) Transverse sections through the embryo in panel C. (D) WISH of 
Glypican-3 at stage 6. Arrowhead indicates the signal in the anterior endoderm. (D’) 
Transverse sections through the embryo in panel D. D, dorsal; V, ventral. 
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Figure 10. The expression pattern of Glypican-3 at stage 7 chick embryo. 
 
(A and B) WISH of Glypican-3 at stage 7. (a1-3) Sagittal sections through the embryo in panel 
A. (b1-3) Transverse sections through the embryo in panel B. 
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Figure 11. The expression pattern of Glypican-3 at stage 8 and 8
+
 chick embryo. 
 
(A) WISH of Glypican-3 at stage 8. (a1-3) Sagittal sections through the embryo in panel A. (B) 
WISH of Glypican-3 at stage 8
+
. (b1-4) Transverse sections through the embryo in panel B. 
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Figure 12. The expression pattern of Glypican-3 at stage 9 and 9
+
 chick embryo. 
 
(A) WISH of Glypican-3 at stage 9. (a1-4) Transverse sections through the embryo in panel A. 
(B) WISH of Glypican-3 at stage 9
+
. (b1-3) Sagittal sections through the embryo in panel B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
stage 9 
A 
a1               a2 
  
 
a3               a4 
a1  
a2  
a3 
a4 
 stage 9
+ 
B 
 
b1 
  
 
 
 
b2  
 
 
 
 
 
b3 
 
 
 
b1  b3 
   b2 
 
 
 51 
 
Figure 13. The expression pattern of Glypican-3 at stage 10
-
 and 10 chick embryo. 
 
(A) WISH of Glypican-3 at stage 10
-
. (a1-6) Transverse sections through the embryo in panel 
A. (B) WISH of Glypican-3 at stage 10. (b1-6) Transverse sections through the embryo in 
panel B. 
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Figure 14. The expression pattern of Glypican-3 at stage 10
+
 and 11
-
 chick embryo. 
 
(A) WISH of Glypican-3 at stage 10
+. (A’) Sagittal section through the embryo in panel A. (B) 
WISH of Glypican-3 at stage 11
-
. (b1-6) Transverse sections through the embryo in panel B. 
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Figure 15. The expression pattern of Glypican-3 at stage 11 and 14 chick embryo. 
 
(A) WISH of Glypican-3 at stage 11. (a1-6) Transverse sections through the embryo in panel A. 
(B) WISH of Glypican-3 at stage 14. Arrowheads indicate the signal in the thyroid, the lung 
and the liver endoderm. (b1-6) Transverse sections through the embryo in panel B.  
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Figure 16. The expression pattern of Glypican-3 at stage 16 and 18 chick embryo. 
 
(A) WISH of Glypican-3 at stage 16. Arrowheads indicate the signal in the thyroid, the lung 
and the liver endoderm. (B) WISH of Glypican-3 at stage 18. Arrowheads indicate the signal in 
the hindgut and the limb bud. 
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Figure 17. A model for the cell proliferation and rearrangement of the endodermal cells in the 
ventral foregut during the foregut elongation. 
 
(A)  The schematic diagram shows the expansion area of the prechordal plate endoderm (top) 
and the proliferating area of the endodermal cells in the ventral foregut (bottom) between the 
before and after foregut elongation. The prechordal plate endoderm in stage 6 spread into 
whole ventral midline in stage 10 (top) (Matsuo, unpublished). Between stage 6 and 8, 
proliferating cells were observed in the whole foregut endoderm. (B) The schematic diagram 
shows the expansion area of AIP midline cells (top) and the proliferating area of the 
endodermal cells in the ventral foregut (bottom) during rapid foregut elongation. The 
expansion area of AIP midline cells is restricted posteriorly as the foregut developed and this 
area is consistent with non-proliferating area in the ventral midline. (C) The schematic diagram 
shows the expansion area of AIP midline cells (top) and proliferating area of the endodermal 
cells in the ventral foregut (bottom) after rapid foregut elongation. There was no expansion of 
AIP midline cells, a few endodermal cells in the ventral midline of the foregut proliferated 
again. 
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